All In Biotech

Drug Trial Radar · NCT07924267

A Single Ascending Dose and Multiple Ascending Dose Trial to Assess the Dose, the Efficacy and Oro-sensitivity of Two Modified Linoleic Acids NKS-3 and NKS-5

A Single Ascending Dose and Multiple Ascending Dose Single-blind, Placebo-controlled, Randomized, Monocentric Trial to Assess the Dose, the Efficacy and Oro-sensitivity of Two Modified Linoleic Acids NKS-3 and NKS-5

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

Dec 10, 2025

Primary completion

Oct 10, 2026

Study completion Oct 26, 2026

Sponsor

Lead sponsor
EktaHIndustry
Sponsor type
Industry
First posted
Nov 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is designed as a single ascending dose and multiple ascending dose single-blind, placebo controlled, randomized, monocentric trial. 60 obese men and women will be recruited for single ascending dose (Groups 1,2,3), according to the following inclusion and non-inclusion criteria. 60 obese men and women will be recruited for multiple ascending doses (Groups 4,5,6), according to the following inclusion and non-inclusion criteria.

Conditions

  • Obesity & Overweight
  • Overweight (BMI > 30)

Interventions

  • NKS-3Drug

    Investigational product is a modified linoleic acid, named NKS-3. This non-caloric agent, synthetized from linoleic acid, is a fat taste receptors agonist, targeting CD36 with also an impact on GPR120

  • NKS-5Drug

    Investigational product is a modified linoleic acid, named NKS-5. This non-caloric agent, synthetized from linoleic acid, is a fat taste receptors agonist, targeting CD36 with also an impact on GPR120

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess the release of satiety peptides (PYY, CCK, GLP-1) at different dosesTime frame: 8 to 10 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Service des Maladies de la Nutrition A, Institut National de nutrition de Tunis

    Tunis, Tunisia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.